Key Takeaways A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its ...

(Reuters) -Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of ...

An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner companies.

Regeneron Pharmaceuticals Inc. (REGN) and French drug major Sanofi S.A. (SNYNF,SNY) announced Friday that Itepekimab met the primary endpoint in one of two trials of chronic obstructive pulmonary ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Sanofi and Regeneron said that drug candidate Itepekimab didn’t meet primary endpoint in a phase three study, although a ...

About the Itepekimab COPD Trial Program AERIFY ... and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary ...

Regeneron and partner Sanofi were studying the drug, which some analysts expect could bring in peak sales of as much as $5 billion, for treating chronic obstructive pulmonary disease (COPD).

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial. A second test of the drug, itepekimab, was successful.